Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability

Jasmine Zain, Avyakta Kallam

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


T cell lymphomas are a heterogenous group with varying biological and clinical features that tend to have poor outcomes with a few exceptions. They account for 10-15% of all non-Hodgkin lymphomas (NHL), and 20% of aggressive NHL. There has been little change in the overall prognosis of T cell lymphomas over the last 2 decades. Most subtypes carry an inferior prognosis when compared to the B cell lymphomas, with a 5-year OS of 30%. Gene expression profiling and other molecular techniques has enabled a deeper understanding of these differences in the various subtypes as reflected in the latest 5th WHO and ICC classification of T cell lymphomas. It is becoming increasingly clear that therapeutic approaches that target specific cellular pathways are needed to improve the clinical outcomes of T cell lymphomas. This review will focus on nodal T cell lymphomas and describe novel treatments and their applicability to the various subtypes.

Original languageEnglish (US)
Article number1150715
JournalFrontiers in Oncology
StatePublished - 2023
Externally publishedYes


  • T cell lymphoma
  • TFH-cell lymphoma
  • anaplastic large cell lymphoma
  • novel therapies
  • updated classification

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability'. Together they form a unique fingerprint.

Cite this